Publication | Open Access

METTL3 inhibition induced by M2 macrophage-derived extracellular vesicles drives anti-PD-1 therapy resistance via M6A-CD70-mediated immune suppression in thyroid cancer

Cancer ImmunosurveillanceMettl3 InhibitionAnti-pd-1 Therapy ResistanceImmunologyTumor ImmunityImmune Checkpoint InhibitorImmunotherapyMedicineCell BiologyThyroid Cancer